89Zr标记西妥昔单抗PET/CT作为RAS野生型晚期结直肠癌西妥昔单抗单药治疗生物标志物的研究
该研究评估了[89Zr]Zr-cetuximab PET/CT肿瘤摄取能否预测RAS野生型转移性结直肠癌患者接受西妥昔单抗单药治疗的获益。35例患者中66%可见肿瘤摄取,但PET阳性与治疗获益、无进展生存和总生存均无显著相关性,80%无摄取患者仍获治疗获益,提示该显像不适合作为预测生物标志物。BRAF突变、右半结肠及低sEGFR与内在耐药相关。
要点
- 肿瘤摄取阳性率66%,但阳性与治疗获益无显著相关(P=0.16)。
- 无摄取患者80%获治疗获益,该PET/CT不适合作为预测标志物。
- BRAF突变、右半结肠和低sEGFR与西妥昔单抗内在耐药相关。
核心结论
- [89Zr]Zr-cetuximab PET/CT肿瘤摄取未能预测RAS野生型mCRC患者西妥昔单抗单药治疗获益。
- BRAF突变、右半结肠及低sEGFR与西妥昔单抗内在耐药相关。
研究设计与样本
- 前瞻性研究,35例RAS野生型晚期结直肠癌患者。
- 治疗前给予西妥昔单抗500 mg/m2(≤2 h)后行[89Zr]Zr-cetuximab(37 MBq/10 mg)PET/CT。
- 无视觉肿瘤摄取者接受剂量递增(750-1250 mg/m2)并复查PET/CT。
- 治疗获益定义为8周CT评估稳定或缓解。
主要发现
- 66%患者可见肿瘤摄取。
- PET阳性与PET阴性患者治疗获益分别为52%与80%(P=0.16)。
- 无进展生存3.6个月 vs 5.7个月(P=0.15),总生存7.1个月 vs 9.4个月(P=0.29)。
- 67%无摄取患者接受剂量递增,第二次PET/CT均无阳性。
- 肿瘤SUVpeak与CT肿瘤大小变化(P=0.23)、治疗获益及无进展生存均无相关性。
关键数值与推荐
- 治疗获益定义为8周CT评估稳定或缓解。
- 剂量递增范围为750-1250 mg/m2。
- BRAF突变、右半结肠及低sEGFR与内在耐药相关。
临床怎么用
- 基于当前证据,[89Zr]Zr-cetuximab PET/CT不应用于筛选西妥昔单抗单药治疗获益人群。
- BRAF突变、右半结肠及低sEGFR可作为内在耐药的参考因素。
- 无肿瘤摄取者仍可能从西妥昔单抗治疗中获益,不应据此排除治疗。
局限性
- 67%无摄取患者接受了剂量递增,可能影响该组结局解读。
- 样本量有限(35例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. PATIENTS AND METHODS: PET/CT imaging of [89Zr]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m2 ≤ 2 h) cetuximab was performed at the start of treatment. Patients without visual tumor uptake underwent dose escalation and a subsequent [89Zr]Zr-cetuximab PET/CT. Treatment benefit was defined as stable disease or response on CT scan evaluation after 8 weeks. RESULTS: Visual tumor uptake on [89Zr]Zr-cetuximab PET/CT was observed in 66% of 35 patients. There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29). However, in 67% of PET-negative patients, cetuximab dose escalation (750-1250 mg/m2) was applied, potentially influencing outcome in this group. None of the second [89Zr]Zr-cetuximab PET/CT was positive. Eighty percent of patients without visual tumor uptake had treatment benefit, making [89Zr]Zr-cetuximab PET/CT unsuitable as a predictive biomarker. Tumor SUVpeak did not correlate to changes in tumor size on CT (P = 0.23), treatment benefit, nor progression-free survival. Cetuximab pharmacokinetics were not related to treatment benefit. BRAF mutations, right-sidedness, and low sEGFR were correlated with intrinsic resistance to cetuximab. CONCLUSION: Tumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients with RAS wild-type mCRC receiving cetuximab monotherapy. BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab.
引用
- van Helden EJ, Elias SG, Gerritse SL, et al. [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31705176. doi:10.1007/s00259-019-04555-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。